Frank MS, Bodtger U, Høegholm A, et al. - Given that re-biopsy in progressive advanced non-small-cell lung cancer (NSCLC) following first line treatment may unveil information regarding evolving tumor biology during treatment, researchers focused on the feasibility, complication risk, as well as clinical relevance of performing re-biopsy systematically. In this prospective single-center study, they analyzed NSCLC patients with advanced, non-targetable disease taking first line systemic treatment. Re-biopsy was performed in 51 patients with progressive advanced NSCLC. Chemotherapy-treated patients had a significantly higher likelihood of PD-L1 tumor proportion score change vs those treated with immunotherapy. Based on the findings, experts concluded that it is feasible to perform re-biopsy, and re-biopsy was associated with low risk of complications and can have clinical relevance in patients with suspected progression in advanced NSCLC.